{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:07:52Z","timestamp":1792062472448,"version":"4.4.0"},"reference-count":39,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy and safety of naltrexone in pediatric patients with autistic disorder (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>Using the terms pediatric, child, naltrexone, autism, and autistic disorder, a literature search was performed using MEDLINE (1966\u2013May 18, 2006) and the International Pharmaceutical Abstracts (1971\u2013May 18, 2006) database. The references of these articles were scanned for additional relevant literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All articles describing or evaluating the efficacy and\/or safety of naltrexone in pediatric patients with AD were included in this review. Three case reports, 8 case series, and 14 clinical studies were identified as pertinent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Naltrexone has been used most commonly at doses ranging from 0.5 to 2 mg\/kg\/day and found to be predominantly effective in decreasing self-injurious behavior. Naltrexone may also attenuate hyperactivity, agitation, irritability, temper tantrums, social withdrawal, and stereotyped behaviors. Patients may also exhibit improved attention and eye contact. Transient sedation was the most commonly reported adverse event. Small sample size, short duration, and inconsistent evaluative methods characterize the available research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>A child affected by AD may benefit from a trial of naltrexone therapy, particularly if the child exhibits self-injurious behavior and other attempted therapies have failed. Serious adverse effects have not been reported in short-term studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1g499","type":"journal-article","created":{"date-parts":[[2006,5,31]],"date-time":"2006-05-31T05:07:35Z","timestamp":1149052055000},"page":"1086-1095","source":"Crossref","is-referenced-by-count":62,"title":["Pediatrics Efficacy and Safety of Naltrexone Use in Pediatric Patients with Autistic Disorder"],"prefix":"10.1177","volume":"40","author":[{"given":"Gladys M","family":"Eichaar","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Practice, College of Pharmacy and Allied Health Professions, St. John's University, Queens, NY; Clinical Coordinator, Pediatric Pharmacy Sen\/ices, Department of Pharmacy, Schneider Children's Hospital, New Hyde Park, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M","family":"Maisch","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Practice, Collegee of Pharmacy and Allied Health Professions, St. John's University;, Drug Information Services, Department of Pharmacy, Long Island Jewish Medical Center, New Hyde Park"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M Gianni","family":"Augusto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Practice, College of Pharmacy and Allied Health Professions, St. John's University;, Drug Information Services, Department of Pharmacy, Long Island Jewish Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J","family":"Wehring","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Practice, College of Pharmacy and Allied Health Professions, St. John's University; Clinical Coordinator, Psychiatric Pharmacy, Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2006,6]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Diagnostic and statistical manual of mental disorders","author":"First MB","year":"2000","unstructured":"First MB, ed. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.","edition":"4"},{"key":"e_1_2_1_3_2","volume-title":"Autism spectrum disorders (pervasive developmental disorders)","author":"Strode M.","year":"2004","unstructured":"Strode M. Autism spectrum disorders (pervasive developmental disorders). NIH publication no. NIH-04-5511. Bethesda, MD: National Institute of Mental Health, National Institutes of Health, US Department of Health and Human Resources. 2004. www.nimh.nih.gov\/publicat\/autism.cfm (accessed 2004 Jan 20)."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291799008508"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198709000-00014"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.146.2.194"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004703-199510000-00002"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.5.1155"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.1.49"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-1958"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307380401900301.155"},{"issue":"4","key":"e_1_2_1_12_2","first-page":"16","article-title":"Treatment of aggression in children and adolescents with autism and conduct disorder","volume":"64","author":"McDougle CJ","year":"2003","unstructured":"McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry 2003;64(suppl 4): 16\u201325.","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(79)90071-7"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220419"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91525-5"},{"key":"e_1_2_1_16_2","first-page":"135","article-title":"Naltrexone in infantile autism","volume":"24","author":"Campbell M","year":"1988","unstructured":"Campbell M, Adams P, Small AM, Tesch LM, Cunen EL. Naltrexone in infantile autism. Psychopharmacol Bull 1988;24:135\u20139.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198903000-00009"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000480957"},{"key":"e_1_2_1_19_2","first-page":"644","article-title":"Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis","volume":"93","author":"Barrett RP","year":"1989","unstructured":"Barrett RP, Feinstein C, Hole WT. Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis. Am J Ment Retard 1989;93:644\u201351.","journal-title":"Am J Ment Retard"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02284716"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02284764"},{"key":"e_1_2_1_22_2","first-page":"169","article-title":"Naltrexone open trial with a 5-year-old-boy. A social rebound reaction","volume":"55","author":"Lensing P","year":"1992","unstructured":"Lensing P, Klingler D, Lampi C., Naltrexone open trial with a 5-year-old-boy. A social rebound reaction. Acta Paedopsychiatr 1992; 55:169\u201373.","journal-title":"Acta Paedopsychiatr"},{"key":"e_1_2_1_23_2","first-page":"19","article-title":"The effects of naltrexone in autistic children: report of two cases","volume":"37","author":"Akkok F.","year":"1995","unstructured":"Akkok F. The effects of naltrexone in autistic children: report of two cases. Turk J Pediatr 1995;37:19\u201323.","journal-title":"Turk J Pediatr"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005674016014"},{"key":"e_1_2_1_25_2","first-page":"130","article-title":"Naltrexone in autistic children: a double-blind and placebo-controlled study","volume":"26","author":"Campbell M","year":"1990","unstructured":"Campbell M, Anderson LT, Small AM, Locascio JJ, Lynch NS, Chorocco MC. Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacol Bull 1990;26:130\u20135.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01058158"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199311000-00024"},{"key":"e_1_2_1_28_2","first-page":"221","article-title":"Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children","volume":"29","author":"Ernst M","year":"1993","unstructured":"Ernst M, Devi L, Silva RR, . Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children. Psychopharmacol Bull 1993;29:221\u20137.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_29_2","first-page":"203","article-title":"Naltrexone plasma levels, clinical response and effect on weight in autistic children","volume":"30","author":"Gonzalez NM","year":"1994","unstructured":"Gonzalez NM, Campbell M, Small AM, . Naltrexone plasma levels, clinical response and effect on weight in autistic children. Psychopharmacol Bull 1994;30:203\u20138.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(95)02749-M"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(95)02601-R"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199502000-00018"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(95)00297-9"},{"key":"e_1_2_1_34_2","first-page":"351","article-title":"Opioid-immune interactions in autism: behavioural and immunological assessment during a doubleblind treatment with naltrexone","volume":"32","author":"Scifo R","year":"1996","unstructured":"Scifo R, Cioni M, Nicolosi A., Opioid-immune interactions in autism: behavioural and immunological assessment during a doubleblind treatment with naltrexone. Ann Ist Super Sanita 1996;32:351\u20139.","journal-title":"Ann Ist Super Sanita"},{"key":"e_1_2_1_35_2","first-page":"1570","article-title":"Naltrexone in young autistic children: replication study and learning measures","volume":"36","author":"Kolmen BK","year":"1997","unstructured":"Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry 1997;36:1570\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(99)00010-3"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199905000-00021"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023000929040"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199808000-00006"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703101102"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G499","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:48Z","timestamp":1777374468000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1G499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1345\/aph.1G499"],"URL":"https:\/\/doi.org\/10.1345\/aph.1g499","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}